1. Show article details.

    New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia

    Business Wire – 6:59 AM ET 03/26/2020

    Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced that the New England Journal of Medicine has published results from BELIEVE, the pivotal Phase 3 study evaluating the safety and efficacy of Reblozyl f...

  2. Show article details.

    BRIEF-Acceleron To Discontinue Development Of ACE-083

    Reuters – 4:32 PM ET 03/09/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 TRIAL OF ACE-083 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE. * Acceleron Pharma Inc (XLRN) - ACE-083 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENTS IN FUNCTIONAL ENDPOINTS RELATIVE TO PLACEBO. * Acceleron Pharma Inc (XLRN) - ACCELERON TO DISCONTINUE DEVELOPMENT OF ACE-083 Source text for Eikon: Further company coverage:

  3. Show article details.

    Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease

    Business Wire – 4:05 PM ET 03/09/2020

    – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 – Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in...

  4. Show article details.

    BRIEF-Acceleron Reports Qtrly Loss Per Share $0.44

    Reuters – 5:39 PM ET 02/27/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2019 OPERATING AND FINANCIAL RESULTS. * QTRLY COLLABORATION REVENUE$39.3 MILLION VERSUS $3.8 MILLION. * QTRLY LOSS PER SHARE $0.44. * Q4 EARNINGS PER SHARE VIEW $-0.29, REVENUE VIEW $35.9 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  5. Show article details.

    Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

    Business Wire – 4:05 PM ET 02/27/2020

    - REBLOZYL® , a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing - - Multiple clinical presentations reviewed at the 61st American Society of Hematology Annual Meeting...

  6. Show article details.

    Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

    Business Wire – 7:00 AM ET 02/26/2020

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.

  7. Show article details.

    Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020

    Business Wire – 7:00 AM ET 02/18/2020

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.

  8. Acceleron Pharma upgraded to overweight at Morgan Stanley

    MarketWatch – 9:50 AM ET 02/03/2020
  9. Acceleron Pharma stock price target raised to $104 from $48 at SVB Leerink

    MarketWatch – 7:57 AM ET 01/28/2020
  10. Show article details.

    Acceleron Pharma stock soars more than 50% on hypertension drug study

    MarketWatch – 4:22 PM ET 01/27/2020

    Acceleron Pharma Inc. (XLRN) shares surged in the extended session late Monday after the biotech drug maker said its hypertension drug hit key goals in a mid-stage clinical trial. Acceleron shares soared 56% after hours, following a 1.6% rise to close Monday at $52.87. At Monday's close, the company had a market cap of $2.81 billion, according to FactSet.

  11. Show article details.

    BRIEF-Acceleron Says Sotatercept Achieves Primary, Secondary Endpoints In PULSAR Phase 2 Placebo-Controlled Trial

    Reuters – 4:16 PM ET 01/27/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON ANNOUNCES SOTATERCEPT ACHIEVED PRIMARY AND SECONDARY ENDPOINTS IN THE PULSAR PHASE 2 PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. * ACCELERON PHARMA (XLRN) - PLANS TO PRESENT DETAILED REVIEW OF TOPLINE RESULTS FROM PULSAR PHASE 2 TRIAL OF SOTATERCEPT AT MEDICAL CONFERENCE LATER THIS YEAR.

  12. Acceleron Pharma stock rallies more than 50% on drug trial results

    MarketWatch – 4:12 PM ET 01/27/2020
  13. Show article details.

    Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension

    Business Wire – 4:01 PM ET 01/27/2020

    - The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance and other secondary endpoints, including amino-terminal brain natriuretic propeptide, and World Health Organization functional class - - Sotatercept wa...

  14. Show article details.

    BRIEF-Acceleron Announces Change To Executive Management Team

    Reuters – 4:47 PM ET 01/23/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON ANNOUNCES CHANGE TO EXECUTIVE MANAGEMENT TEAM. * Acceleron Pharma Inc (XLRN) - JOHN QUISEL CHIEF BUSINESS OFFICER, IS LEAVING TO BECOME CEO OF A VENTURE-BACKED STARTUP BIOTECHNOLOGY C Source text for Eikon: Further company coverage:

  15. Show article details.

    Acceleron Announces Change to Executive Management Team

    Business Wire – 4:15 PM ET 01/23/2020

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the Company to become Chief Executive Officer of a venture-backed startup biotechnology company.

  16. Show article details.

    New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial

    Business Wire – 6:59 AM ET 01/09/2020

    Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced that the New England Journal of Medicine has published results from MEDALIST, the pivotal phase 3 study evaluating the use of Reblozyl® to treat anemia in patients with very low- to intermediate-ris...

  17. Show article details.

    Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference

    Business Wire – 7:00 AM ET 01/06/2020

    Acceleron Pharma Inc. (XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Page:

Today's and Upcoming Events

  • May
    07

    XLRN to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    27

    XLRN announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.